There is therefore interest in developing new assays to aid both diagnosis and risk stratification in patients with APS, and the primacy of β2GPI as the key autoantigen has informed development of these tests – particularly IgA aβ2GPI [172] and anti-DI antibodies [[173], [174], [175]]. The gene discussed is CD79A; the disease is autoimmune polyendocrinopathy.